Developments in treating metastatic colorectal cancer: Recent international reports from ASCO 2007 and 2008

INTRODUCTION: Treatment for metastatic colorectal cancer (mCRC), employing various schedules, combinations, and regimens utilizing 5-fluorouracil (5-FU), irinotecan, oxaliplatin, capecitabine, bevacizumab, and cetuximab, currently achieves an overall survival that extends to approximately two years....

Descripción completa

Detalles Bibliográficos
Autor principal: Ducreux, Michel
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2009
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3108637/
https://www.ncbi.nlm.nih.gov/pubmed/21694822

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3108637/
https://www.ncbi.nlm.nih.gov/pubmed/21694822

Ejemplares similares